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Microphysiological systems and low-cost
microfluidic platform with analytics
Alec ST Smith1, Christopher J Long1, Bonnie J Berry1, Christopher McAleer1, Maria Stancescu1, Peter Molnar2,
Paula G Miller2, Mandy B Esch2, Jean-Matthieu Prot2, James J Hickman*1 and Michael L Shuler2

Abstract
A multiorgan, functional, human in vitro assay system
or ‘Body-on-a-Chip’ would be of tremendous benefit
to the drug discovery and toxicology industries, as
well as providing a more biologically accurate model
for the study of disease as well as applied and basic
biological research. Here, we describe the advances
our team has made towards this goal, as well as the
most pertinent issues facing further development
of these systems. Description is given of individual
organ models with appropriate cellular functionality,
and our efforts to produce human iterations of each
using primary and stem cell sources for eventual
incorporation into this system. Advancement of the
‘Body-on-a-Chip’ field is predicated on the availability
of abundant sources of human cells, capable of full
differentiation and maturation to adult phenotypes, for
which researchers are largely dependent on stem cells.
Although this level of maturation is not yet achievable
in all cell types, the work of our group highlights
the high level of functionality that can be achieved
using current technology, for a wide variety of cell
types. As availability of functional human cell types
for in vitro culture increases, the potential to produce
a multiorgan in vitro system capable of accurately
reproducing acute and chronic human responses to
chemical and pathological challenge in real time will
also increase.

Introduction
Model physiological systems that integrate diﬀerent
human cell types, while maintaining normal physiological
responses and month-long cell viability in deﬁned, serumfree media, are needed to facilitate the replacement of
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animals in preclinical drug screens with in vitro
platforms. Our team’s philosophy is to keep these systems
as simple as possible to hold down cost and only add
complexity to enable increased functionality, if needed
for better evaluation capabilities. Design of our systems is
guided by a computer model of the body (a physiologically based pharmacokinetic (PBPK) pharmacodynamic model), referred to as a micro-cell culture
analog (μCCA) or a ‘Body-on-a-Chip’. In an article
entitled ‘Tissue Models: A Living System on a Chip’ [1],
Shuler’s group is credited with conceiving of this
approach, and with demonstrating its broad feasibility.
Our in vitro system, unlike other in vitro methods,
provides realistic dose dynamics and allows for metabolite exchange between compartments. Furthermore, the
natural length scale of the model (10 to 100 μm) is
consistent with physiological length scales.
Hickman’s group has developed a deﬁned base media
system that enables culture of a wide range of cell types
for many months, and removes a major variable (serum)
from the system. Hickman’s group published the ﬁrst
serum-free, deﬁned culture system for neurons in 1995
[2] and has since then advanced this work from the use of
rodent cells to human cells. In most cases, the cultured
cells have been shown to maintain functionality for at
least 2 to 3 months in this system. This common, deﬁned
media system utilization has been expanded to include
human neurons [3,4], glia [5,6], muscle [3] and cardiomyocytes [7] from adult, fetal and embryonic stem cell
sources. Hickman’s group has progressed in the creation
of a functional neuromuscular junction model for rat–rat
[8] to rat–human [4] to human–human [3] using the
same basic serum-free culture system.
Owing to space constraints, a complete overview of the
design and validation of all current ‘Body-on-a-Chip’
technologies is beyond the scope of this article. For a more
complete assessment of the ﬁeld, refer to the reviews in
[9,10] and references cited therein. This paper will instead
highlight the advances our group has made in developing a
multiorgan ‘Body-on-a-Chip’ platform, as well as our
achievements in developing functional assays of a variety
of tissues for eventual integration into this model.
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Design and validation of a multiorgan in vitro
system
The fabrication of a microﬂuidic device that used living
cell tissue constructs, interconnected as they are in the
body, was conceived by Shuler, Baxter and others (US
Patent #7,288,405 2007). The concept for a ‘Body-on-aChip’ microphysiological system comes from the desire
to emulate a PBPK pharmacodynamic mathematical
model using a physical model. By combining PBPK
pharmacodynamic models with the experimental device,
the quality of predictions and depth of understanding can
be increased [11,12]. Shuler’s group has demonstrated
such a device and its use in emulating key aspects of the
human response to combination treatment of colon
cancer, using tegafur and uracil [12].
This eﬀort is currently being expanded by exploring
designs of devices with up to 13 tissue compartments.
Figure 1 shows the design of a 10-compartment system
currently in development. Measurements can be made
using microscopy, integrated microelectrode arrays, biomicroelectromechanical system (BioMEMS) devices and
using conditioned medium samples sent to microanalytical systems. Initial tests demonstrate that this
system can maintain high cell viability (85 to 95%) in all
compartments using HepG2-C3A cells, over a 48-hour
period, without medium replacement. The ﬂuid ﬂow to
each compartment is consistent with design values, and
the overall blood surrogate recirculation time
(approximately 6 minutes) is consistent with the expected
physiological value.
Cardiac model
The Hickman group has developed an in vitro method for
pharmacological cardiac side-eﬀect testing, which uses
surface-modiﬁed commercially available multi-electrode
arrays (MEAs). The surface of the multi-electrode array is
patterned with a cytophobic polyethylene-glycol selfassembled monolayer, and the cytophilic biopolymer
ﬁbronectin [7]. Rat cardiac myocytes plated onto
patterned multi-electrode arrays are stable in culture for
at least 60 days, and have been used to test functional
responses to two drugs: 1-heptanol, a gap junction
blocker; and sparﬂoxacin, a ﬂuoroquinone antibiotic.
Integration of these systems with BioMEMS cantilever
devices also allows for direct force measurement to be
made.
Central/peripheral nervous system and skeletal
muscle models
The culture parameters for the long-term maintenance
and maturation of both embryonic and adult rat hippocampal neurons in serum-free conditions have been
established by the Hickman group [13]. Such cells are
amenable to interrogation with patch clamp electrodes
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[13] and multi-electrode arrays [14], and display mature
morphology as well as electrical function.
We have published extensively on the establishment of
motoneuron [15,16] and muscle [17] cultures, utilizing
cells from both human stem cell [3,4,15] and rodent
[16,18] sources. Furthermore, our group has detailed the
development of human stem-cell-derived co-cultures for
analysis of neuromuscular junction formation in vitro [3].
Human motoneuron–muscle co-cultures, cultured using
our protocols, have been shown to survive for 30+ days in
vitro and to form synaptic connections responsive to
stimulation with excitatory neurotransmitters (for example, glutamate) and to be inhibited through treatment
with acetylcholine receptor antagonists (for example, dtubocurarine) [3]. Muscle-only systems have been integrated with BioMEMS cantilever chips to allow direct
force readouts of muscle function [17,19,20].
The Hickman laboratory has also demonstrated the
capacity to maintain co-cultures of rat intrafusal muscle
ﬁbers with sensory neurons [21]. Recently, we published
the ﬁrst in vitro culture model capable of diﬀerentiating
and maintaining human, stem-cell-derived sensory
neurons displaying full electrical functionality [22]. We
are currently working on developing a model capable of
replicating all aspects of the reﬂex arc with human cells
in vitro [23].

Lung model
The Hickman and Shuler groups have developed a microﬂuidic device that reproduces the microenvironment of
the lung alveoli, to produce controlled gas concentrations
in both the gas and liquid sides of the alveolus–capillary
interface, and to measure changes in functional gas
transfer through the epithelial–endothelial bilayer [24].
The alveolar microﬂuidic device contains a number of
chambers for microenvironment maintenance and monitoring. The primary chamber was designed to contain the
cellular alveolus–capillary interface construct. An upstream conditioning chamber was incorporated to
control the dissolved gas concentrations in the incoming
liquid, acting as a blood analog, and downstream
chambers were included to house dissolved gas sensors
for monitoring output concentrations. This silicon-based
device allows the control and maintenance of gas concentrations in both gas and liquid chambers. Changes to
the health of the alveoli can be monitored under various
conditions including restricted lung capacity, altered
blood compositions, and disease states involving the
alveolar–capillary interface.
Gastrointestinal tract/liver model
Absorbed drugs that have crossed the gastrointestinal
tract mucosa and epithelium are transported directly to
the liver via the portal vein. ‘Body-on-a-Chip’ constructs,
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Figure 1. Overview of a 10-chamber in vitro model. Overview of our 10-chamber in vitro model based on a simplified three-chamber system
using gravity-driven flow [12]. (A) Prototype unit on a rocker platform. (B) Close-up inverted view of the prototype unit after a dye distribution
study. (C) Exploded schematic showing the compartmentalization design for a 10-chamber system within this single unit. Barrier tissues
(for example, gastrointestinal (GI) tract, skin, and so forth) are made by plating cells and allowing them to grow into a layer on a pretreated
polycarbonate membrane (0.4 μm pore size) that was sandwiched between a chamber gasket and another gasket or a polycarbonate channel
plate creating chambers for the cells. The design provides an apical and a basolateral side for each chamber, allowing passage of chemicals across
the barrier. Nonbarrier tissues are three-dimensional constructs made by resuspending cells in hydrogels or plating them on a polymeric scaffold.
The three-dimensional tissue constructs are placed directly onto a polycarbonate membrane that is again sandwiched between a chamber gasket
and another gasket or polycarbonate channel plate creating the chambers for the cells.

that contain both the gastrointestinal tract and the liver,
can therefore simulate the uptake and ﬁrst-pass metabolism of drugs. The detection of metabolites of acetaminophen within such a system has recently conﬁrmed that
this is possible with a two-organ in vitro model by Shuler
and colleagues [25].
Shuler’s group and others have expanded simple
Caco-2 cell culture models to two-cell-type and threecell-type cultures that consist of Caco-2 cells, mucusproducing HT-29 cells, and M-cells [26,27]. Using this
system Shuler and colleagues have recently simulated the
oral uptake of 50 and 200 nm polystyrene particles, and
have found that M-cells are needed to simulate the
uptake of the larger particles [27]. The group has also
developed microﬂuidic models that contained this threecell-type gastrointestinal tract tissue and simulated the
uptake of acetaminophen and its subsequent actions in
the liver [25]. PBPK simulations of these devices indicated that after 24 hours the acetaminophen dose in the
device was ~90% of that expected in humans after
24 hours. They have begun to culture Caco-2 cells on
three-dimensional surfaces that allow the cells to form

macro-villi, thereby enabling drug transport studies
across a three-dimensional tissue interface [28,29].
Sung and Shuler have developed a micro-device that
uses Matrigel and confers a three-dimensional environment which facilitates the expression of CYP450 enzymes
by cultured hepatocytes [30]. The current work concentrates on the integration of primary hepatocytes with
non-parenchymal cells, cultivated in a three-dimensional
scaﬀold [31], to better mimic the physiological situation.
Initial experiments using non-parenchymal cells and a
HepG2/C3A liver model, cultivated in our gravity-driven
ﬂow device, have shown sustained biological activity for
28 days in vitro, including inducible CYP450 activity
(CYP1A1 and CYP3A4) and albumin synthesis.

Barrier tissues model
Shuler’s approach to modeling the blood–brain barrier is
to utilize microfabricated membranes, which are manufactured as integral parts of microﬂuidic chambers
[28,32], to culture brain endothelial cells and astrocytes
within microﬂuidic chambers. These will enable the
testing of hypotheses related to the need for physical

Smith et al. Stem Cell Research & Therapy 2013, 4(Suppl 1):S9
http://stemcellres.com/content/4/S1/S9

contact between endothelial cells and astrocytes. Recent
work by Lippmann and colleagues [33] and by Shayan
and colleagues [34] has shown that brain endothelial cells
respond to the presence of astrocytes in culture, acquiring substantial barrier properties, as indicated by high
transendothelial electrical resistance measurements.
Shuler’s work in developing an in vitro model of the
capillary network has focused on characterizing endothelial cell (human umbilical vein endothelial cell) growth
in small microﬂuidic vessels (50 μm×50 μm). In vessels of
this size, the sidewalls become signiﬁcant surfaces.
Characterization with confocal microscopy has shown
that human umbilical vein endothelial cells grown in
small microﬂuidic channels exhibit barrier function (as
indicated by immunostained vascular endothelial
cadherin) throughout the vessels and even on the
sidewalls when the cells are cultured under suﬃcient
shear stress [35].

Fat model
Since ‘Body-on-a-Chip’ models must include the complete set of organs either implicitly or explicitly, the fat
compartment is often included implicitly. However,
modeling the fat compartment explicitly may have
advantages. In experiments with environmental toxins
(naphthalene) Shuler has found that the presence of a fat
compartment, represented by diﬀerentiated 3T3-L1
adipocytes, modulates the response of the system (in
particular, lung cells) to the toxin. Adipocytes presumably
ameliorate damage to co-cultured cells through absorption of toxins and damaging compounds, such as
hydrogen peroxide, and prevention of glutathione
depletion [36].
Conclusions
Our groups have focused on developing increasingly
authentic functional tissue constructs to incorporate into
a multi-tissue platform based on a PBPK model. While
there are signiﬁcant challenges in constructing an
integrated 10-organ, all-human system, the advances so
far made by our team lead us to believe we have a good
basis to construct a functional human model. Issues such
as availability, cost, and ability to display adult cell
physiology and phenotype will soon be solved, to allow
greater incorporation of stem cells into these modules
and ultimately more authentic tissue constructs and
improved modules in this microphysiological system.
Abbreviations
BioMEMS, bio-microelectromechanical system; PBPK, physiologically based
pharmacokinetic.
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